Bergonzi E, Herren A, Lavanchy P, Bühlmann C, Wyss S R, Lüthy C, Oetliker O
Helv Paediatr Acta. 1981 Nov;36(5):437-43.
A pilot study with cysteamine treatment was performed in three children with the nephropathic form of cystinosis. Two children underwent renal transplantation shortly before treatment. The aim of the study was to find a practicable form of application and a corresponding effective dose. Cysteamine in gelatine capsules together with 0.2% silicic acid as a dessicator turned out to be the most acceptable galenic form, compared to sirup or suppositories. Among three dosage regimens, the dosage of 50 mg/kg/day is effective as judged by the leucocyte cystine content, even if given in only three doses per day. No side effects of the cysteamine treatment (even at a dose of 90 mg/kg/day) were noted. Whether this treatment is preventing progression of disease will have to be examined either in transplanted patients by measuring non-renal parameters or in very young infants with cystinosis whose kidneys are not damaged yet.
对三名患有肾病型胱氨酸病的儿童进行了半胱胺治疗的初步研究。两名儿童在治疗前不久接受了肾移植。该研究的目的是找到一种可行的给药形式和相应的有效剂量。与糖浆或栓剂相比,明胶胶囊中的半胱胺与作为干燥剂的0.2%硅酸一起被证明是最可接受的药剂形式。在三种给药方案中,根据白细胞胱氨酸含量判断,50mg/kg/天的剂量是有效的,即使每天只给药三次。未观察到半胱胺治疗的副作用(即使在90mg/kg/天的剂量下)。这种治疗是否能阻止疾病进展,将必须在移植患者中通过测量非肾脏参数来检查,或者在肾脏尚未受损的非常年幼的胱氨酸病婴儿中进行检查。